Google
SYRE Stock Analysis — SPYRE THERAPEUTICS INC. (Healthcare >> Biotechnology)
SYRE FAQ
What is SYRE's ROE?
SPYRE THERAPEUTICS INC. reports a Return on Equity (ROE) of -26.75%.
What is SYRE's dividend yield?
SPYRE THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is SYRE's Quality Score?
Our AI rates SYRE's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SYRE?
Our AI Timing Score for SYRE is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SYRE belong to?
SPYRE THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
SYRE AI Analysis Summary
Our AI summary for SYRE: SPYRE THERAPEUTICS INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -26.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 98.33
Price
-3.17
(-3.12%)
Day Change
|
|
|---|
SYRE, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 98.33 |
| PBV / Sector |
13.14 / 5.20
|
| Earning Per Share | -2.00 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
105.02 M
GREAT
|
| Average 1W Daily Value |
92.58 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:33 |
| Symbol | SYRE |
| Name | SPYRE THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 86.84 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,814.39 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 23, Waltham, MA, United States, 02453
Phone: 617 651 5940
Website: https://www.spyre.com
Employees: 112
Sector: Healthcare >> Biotechnology
Description: Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap